Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,258 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Autoimmune Diseases Clear all
Completed Phase 3 Interventional Results available

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

NCT00548405
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
85
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

NCT03714022
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
South Miami, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

Bayer/Cognitive Assessments With Multiple Sclerosis Subjects

NCT00888277
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

NCT01098201
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Feasibility Trial Testing the Bionic Pancreas With ZP4207

NCT02971228
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
Drug · Device
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03738865
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Novo Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Walnut Creek, California • Atlanta, Georgia • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 20, 2026, 8:23 AM EDT
Suspended No phase listed Observational

Sjogren's Lung Study

NCT04843345
View directory record Official record
Conditions
Sjogren's Syndrome, Interstitial Lung Disease, Primary Pulmonary Lymphoma (Disorder), Chronic Bronchiolitis, Bronchiectasis, Lung Diseases, Cystic Lung Disease, Lymphocytic Interst. Pneumonitis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

NCT04980495
View directory record Official record
Conditions
Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG
Interventions
Efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU

NCT05857007
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

NCT01236534
View directory record Official record
Conditions
Multiple Sclerosis, Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

NCT00995722
View directory record Official record
Conditions
Ocular Myasthenia Gravis
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Michael Benatar
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
New Haven, Connecticut • Miami, Florida • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

NCT03046251
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Active, not recruiting Not applicable Interventional

Functional Outcomes From Diets in Multiple Sclerosis

NCT05327322
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Glycemic load, Calorie restriction, Behavioral support
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

NCT03347422
View directory record Official record
Conditions
Cold Agglutinin Disease
Interventions
sutimlimab (BIVV009), placebo
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

NCT01319331
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes
Interventions
Alpha 1-Antitrypsin (AAT, Aralast NP)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

NCT01198002
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 20, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Blood Flow Restriction And Veterans With MS

NCT05433103
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Low-Load Exercise with Blood Flow Restriction, Low-Load Exercise Control Group
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

Description of Patients With Type 1 Diabetes Treated With Teplizumab

NCT06892002
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
24
States / cities
Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

NCT01386437
View directory record Official record
Conditions
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Not applicable Interventional

School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus

NCT00566475
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
telemedicine
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
5 Years to 14 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Therapies for Down Syndrome Regression Disorder

NCT05662228
View directory record Official record
Conditions
Down Syndrome, Regression
Interventions
Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

NCT04516967
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

T and B Cell Responses in Autoimmune Diseases

NCT01947036
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 20, 2026, 8:23 AM EDT